Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis

An announcement from Cardiol Therapeutics ( (TSE:CRDL) ) is now available.

On January 13, 2026, Cardiol Therapeutics announced it has surpassed 50% patient enrollment in MAVERIC, its pivotal Phase III international trial evaluating oral therapy CardiolRx™ to prevent disease recurrence in patients with recurrent pericarditis. The company has more than 15 cardiovascular centers actively enrolling in the United States, is adding top-tier sites in Europe and Canada, and expects to complete enrollment in the second quarter of 2026, an execution milestone that reduces clinical risk for its lead registrational program and underscores strong physician demand for alternatives to corticosteroids and immunosuppressive biologics. MAVERIC, which aims to enroll about 110 patients at roughly 25 sites, is built on positive Phase II MAvERIC-Pilot results showing reductions in pain, inflammation, and recurrence, and is designed to assess freedom from new episodes of recurrent pericarditis and other efficacy measures after six months of double-blind treatment, positioning CardiolRx™ as a potential differentiated, non-immunosuppressive option in a market where existing biologic therapies are forecast to generate substantial U.S. revenues.

The most recent analyst rating on (TSE:CRDL) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.

Spark’s Take on TSE:CRDL Stock

According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Neutral.

The score is primarily held back by weak financial performance (ongoing losses and cash burn with equity erosion) and bearish technicals (below key moving averages with negative MACD). Positive corporate events (trial progress and financing extending runway) provide some offset, while valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on TSE:CRDL stock, click here.

More about Cardiol Therapeutics

Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx™, targets inflammasome pathway activation implicated in pericarditis, myocarditis, and heart failure, and is being advanced through the MAVERIC program in recurrent pericarditis and the ARCHER program in acute myocarditis. The company is also developing CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure, with its programs supported by prior Phase II data and Orphan Drug Designation from the U.S. FDA for pericarditis.

Average Trading Volume: 112,545

Technical Sentiment Signal: Sell

Current Market Cap: C$139.5M

See more insights into CRDL stock on TipRanks’ Stock Analysis page.